To study the acute and direct effects of GnRH agonists preovulatory follicles were isolated from PMSG-treated immature rats and incubated for 15-360 min in modified Kreb's bicarbonate buffer. The levels of cAMP, prostaglandin E, and progesterone were analysed in the tissue and/or incubation media. GnRH and two GnRH agonists produced a dose-dependent stimulation of progesterone production with maximal levels 5-6-fold higher than the control group. As compared to LH the magnitude of this effect was small and was detected only after 240-360 min of incubation. GnRH also stimulated prostaglandin E accumulation and this effect was as pronounced as for LH. There were no detectable changes in cAMP levels for any concentration of GnRH when the incubation time varied between 15 and 120 min whether or not a phosphodiesterase inhibitor was present, but after 240 min of incubation a 2-fold increase in cAMP was found. Consistent with previous results, LH caused a pronounced (40-50-fold) increase in follicular cAMP which was already detectable after 15 min of incubation. Indomethacin abolished the rise in prostaglandin E induced either by GnRH or LH but did not affect the response in terms of cAMP or progesterone, and did not affect the stimulation of meiotic maturation of the follicle-enclosed oocytes caused by the hormones. It is concluded that GnRH can exert acute and LH-like stimulatory effects on the preovulatory rat follicle but that the mechanism of GnRH action is different from that of LH.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1530/acta.0.1010603 | DOI Listing |
Front Endocrinol (Lausanne)
December 2024
Taiwan United Birth-Promoting Experts Fertility Clinic, Tainan, Taiwan.
Objectives: This study aimed to investigate the correlation of ovarian sensitivity index (OSI) and clinical parameters in IVF treatments.
Methods: IVF data files between January 2011 and December 2020 in a single unit were included. The primary outcome measure was the correlation between the OSI and clinical pregnancy and live birth rates.
J Obstet Gynaecol
December 2025
Department of Gynecology, Zunhua People's Hospital, Zunhua, Hebei, China.
Background: The gonadotropin-releasing hormone antagonist (GnRH-ant) protocol is associated with few oocytes retrieved, few mature oocytes and poor endometrial receptivity. Omission of GnRH-ants on trigger day seems unlikely to induce preovulation and may improve outcomes in the GnRH-ant protocol. This study aimed to systematically evaluate the effects of GnRH-ant cessation on trigger day on in vitro fertilisation outcomes following the GnRH-ant protocol.
View Article and Find Full Text PDFCell Rep Med
December 2024
Department of Medical Oncology, National Taiwan University Cancer Center, Taipei City 106, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City 100, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei City 100, Taiwan. Electronic address:
The efficacy of immunotherapy for estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC) has not been proven. We conduct a phase 1b/2 trial to assess the efficacy of combining pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist) for 15 patients with premenopausal ER+/HER2- MBC who had failed one to two lines of hormone therapy (HT) without chemotherapy. The primary endpoint of progression-free survival rate at 8 months (i.
View Article and Find Full Text PDFGynecol Obstet Invest
December 2024
Background: No conceptually new drugs for the safe and successful cure of endometriosis are likely to become available soon. Hormonal modulation of ovarian function and suppression of menstruation remain the pillars of disease control. However, existing drugs may be used following novel modalities to limit the consequences of endometriosis progression.
View Article and Find Full Text PDFExpert Opin Drug Saf
December 2024
Unit of Obstetrics and Gynecology, Chiavari, Genoa, Italy.
Introduction: Endometriosis and pelvic inflammatory disease (PID) are gynecological conditions affecting women of reproductive age and causing pain symptoms. The symptoms caused by these conditions are similar; thus, the differential diagnosis may be challenging. The treatment of these conditions is very different because PID is treated with antibiotic therapy, while endometriosis is treated with hormonal therapies suppressing estrogen levels.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!